The observed results reinforce the potential of GH-RH antagonists as a viable therapeutic option for BPH, particularly when used in combination with other treatments and perhaps with LH-RH antagonists (Fig. 2). The gene discussed is GNRH1; the disease is benign prostatic hyperplasia.